The multidrug-resistance gene in gene therapy of cancer and hematopoietic disorders.

Abstract

Chemoresistance genes have been identified as an impediment to anticancer drug treatment. In particular, P-glycoprotein, the product of the multidrug-resistance (MDR1) gene, plays a major role in clinical treatment failure. Conversely, expression of an MDR1 cDNA in bone marrow of transgenic animals renders hematopoietic cells chemoresistant. Efficient transfer of drug-resistance genes to normal hematopoietic progenitor cells has been achieved with the use of retroviral vectors. In this article we review approaches which use the multidrug-resistance gene to protect bone marrow from myelosuppression following chemotherapy and as a selectable markerin vivo to increase the expression of nonselectable genes which correct hereditary diseases of the hematopoietic system.

• Authors: T Licht, I Pastan, M M Gottesman, F Herrmann
• Journal: Annals of hematology (Ann Hematol) Vol. 72 Issue 4 Pg. 184-93 (Apr 1996) ISSN: 0939-5555 [Print] Germany
• PMID: 8624371 (Publication Type: Journal Article, Review)

Chemical References

• ATP Binding Cassette Transporter, Subfamily B, Member 1

Topics

• ATP Binding Cassette Transporter, Subfamily B, Member 1 (genetics)
• Genetic Therapy
• Hematologic Diseases (genetics, therapy)
• Humans
• Neoplasms (genetics, therapy)